Where do oral selective estrogen receptor degraders (SERDs) fit in the overall landscape of first- and second-line advanced/metastatic breast cancer?

Credit available for this activity expires: 12/04/26
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/how-are-oral-serds-changing-management-advanced-hr-positive-2025a1000xkg?ecd=bdc_podcast_libsyn_mscpedu